Literature DB >> 22921088

Emtricitabine/rilpivirine/tenofovir disoproxil fumarate single-tablet regimen: a guide to its use in HIV-1 infection.

Katherine A Lyseng-Williamson1, Lesley J Scott.   

Abstract

The once-daily, single-tablet regimen of emtricitabine/rilpivirine/tenofovir disoproxil fumarate (Eviplera™ [EU]; Complera™ [US]) provides a convenient option for antiretroviral therapy in treatment-naive patients with HIV-1 infection. In well designed trials in this patient population, rilpivirine plus emtricitabine/tenofovir disoproxil fumarate was noninferior to efavirenz plus emtricitabine/tenofovir disoproxil fumarate in terms of reducing viral HIV-1 RNA level to <50 copies/mL and was generally better tolerated than efavirenz plus emtricitabine/tenofovir disoproxil fumarate.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22921088     DOI： 10.1007/bf03261925

Source DB:  PubMed          Journal:  Clin Drug Investig        ISSN： 1173-2563            Impact factor:   2.859


  12 in total

Review 1.  Mitochondrial toxicity of NRTI antiviral drugs: an integrated cellular perspective.

Authors:  William Lewis; Brian J Day; William C Copeland
Journal:  Nat Rev Drug Discov       Date:  2003-10       Impact factor: 84.694

Review 2.  Recent advances in antiretroviral treatment and prevention in HIV-infected patients.

Authors:  Fernando Maltêz; Manuela Doroana; Teresa Branco; Cristina Valente
Journal:  Curr Opin HIV AIDS       Date:  2011-12       Impact factor: 4.283

3.  Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the phase 3 ECHO and THRIVE studies: 48-week analysis.

Authors:  Laurence Rimsky; Johan Vingerhoets; Veerle Van Eygen; Joseph Eron; Bonaventura Clotet; Annemie Hoogstoel; Katia Boven; Gaston Picchio
Journal:  J Acquir Immune Defic Syndr       Date:  2012-01-01       Impact factor: 3.731

Review 4.  HIV-1 resistance to first- and second-generation non-nucleoside reverse transcriptase inhibitors.

Authors:  Jade Ghosn; Marie-Laure Chaix; Constance Delaugerre
Journal:  AIDS Rev       Date:  2009 Jul-Sep       Impact factor: 2.500

5.  Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials.

Authors:  Calvin J Cohen; Jean-Michel Molina; Pedro Cahn; Bonaventura Clotet; Jan Fourie; Beatriz Grinsztejn; Hao Wu; Margaret A Johnson; Michael Saag; Khuanchai Supparatpinyo; Herta Crauwels; Eric Lefebvre; Laurence T Rimsky; Simon Vanveggel; Peter Williams; Katia Boven
Journal:  J Acquir Immune Defic Syndr       Date:  2012-05-01       Impact factor: 3.731

6.  Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial.

Authors:  Jean-Michel Molina; Pedro Cahn; Beatriz Grinsztejn; Adriano Lazzarin; Anthony Mills; Michael Saag; Khuanchai Supparatpinyo; Sharon Walmsley; Herta Crauwels; Laurence T Rimsky; Simon Vanveggel; Katia Boven
Journal:  Lancet       Date:  2011-07-16       Impact factor: 79.321

7.  Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial.

Authors:  Calvin J Cohen; Jaime Andrade-Villanueva; Bonaventura Clotet; Jan Fourie; Margaret A Johnson; Kiat Ruxrungtham; Hao Wu; Carmen Zorrilla; Herta Crauwels; Laurence T Rimsky; Simon Vanveggel; Katia Boven
Journal:  Lancet       Date:  2011-07-16       Impact factor: 79.321

Review 8.  Nonnucleoside reverse transcriptase inhibitor resistance and the role of the second-generation agents.

Authors:  Jessica Adams; Nimish Patel; Nancy Mankaryous; Mariam Tadros; Christopher D Miller
Journal:  Ann Pharmacother       Date:  2009-12-08       Impact factor: 3.154

Review 9.  Rilpivirine.

Authors:  Mark Sanford
Journal:  Drugs       Date:  2012-03-05       Impact factor: 9.546

Review 10.  Etravirine and rilpivirine: nonnucleoside reverse transcriptase inhibitors with activity against human immunodeficiency virus type 1 strains resistant to previous nonnucleoside agents.

Authors:  Patricia Pecora Fulco; Ian R McNicholl
Journal:  Pharmacotherapy       Date:  2009-03       Impact factor: 4.705
View more
  3 in total

1.  Optimization of diarylazines as anti-HIV agents with dramatically enhanced solubility.

Authors:  Mariela Bollini; José A Cisneros; Krasimir A Spasov; Karen S Anderson; William L Jorgensen
Journal:  Bioorg Med Chem Lett       Date:  2013-07-08       Impact factor: 2.823

2.  The connection domain mutation N348I in HIV-1 reverse transcriptase enhances resistance to etravirine and rilpivirine but restricts the emergence of the E138K resistance mutation by diminishing viral replication capacity.

Authors:  Hong-Tao Xu; Susan P Colby-Germinario; Maureen Oliveira; Yingshan Han; Yudong Quan; Veronica Zanichelli; Mark A Wainberg
Journal:  J Virol       Date:  2013-11-13       Impact factor: 5.103

3.  Triple-combination rilpivirine, emtricitabine, and tenofovir (Complera™/Eviplera™) in the treatment of HIV infection.

Authors:  Claudia Bernardini; Franco Maggiolo
Journal:  Patient Prefer Adherence       Date:  2013-06-19       Impact factor: 2.711
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.